Exicure, Inc. (XCUR)
Chart Events
Performance Outlook
| Previous Close | 0.1215 |
| Open | 0.1200 |
| Bid | 0.1250 x 1400 |
| Ask | 0.1254 x 1300 |
| Day's Range | 0.1200 - 0.1319 |
| 52 Week Range | 0.0950 - 1.9800 |
| Volume | |
| Avg. Volume | 13,432,077 |
| Market Cap | 15.338M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6190 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.13 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for XCUR
Related Research
- Exicure, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.RatingFair ValueEconomic Moat20 hours agoMorningstar
- Business Wire
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
CHICAGO, May 17, 2022--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.
- Business Wire
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
CHICAGO, May 16, 2022--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.
- Business Wire
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
CHICAGO, May 10, 2022--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that it has agreed to sell an aggregate of 26,021,111 shares of its common stock at a purchase price of $0.1937 per share to certain accredited investors in a private placement in public equity ("PIPE") financing. The purch
